poisar

Stocks · News reference

Tandem Diabetes Care Receives FDA Clearance for Tubeless Tandem Mobi System

Fiscal.ai

Tandem Diabetes Care announced U.S. FDA clearance for the Tandem Mobi system, enabling it to function as a tubeless automated insulin delivery system with up to seven days of wear.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading